报告期内，公司三大主业同步向好，国际业务占比持续提升。第三季度，公司生命信息与支持产线三季 度收入29.52亿元，同比增长2.60%，微创外科业务收入同比增长超25%，国际收入占比升至70%；医学 影像产线收入16.89亿元，国际业务收入同比高个位数增长，前三季度国际收入占该产线比重达61%， 超高端超声前三季度收入翻倍；体外诊断产线第三季度收入36.34亿元，国际业务收入双位数增长，前 三季度国际收入占该产线比重达37%。其中，全实验室自动化流水线国内装机180套（接近去年全 年），国际销售超20套（提前完成全年任务），化学发光等重点业务市占率稳步提升。 国际化布局持续深化的同时，公司海外本地化能力也不断增强。迈瑞医疗自2000年开启国际化战略，目 前已在全球除美国外的14个国家布局生产基地（含FDA认证工厂），通过高端客户突破与均衡区域分 布，实现海外业务高基数增长。公司表示，未来将进一步完善全球供应链与服务保障体系，强化国际市 场韧性。 本报讯 （记者刘晓一）10月29日晚间，深圳迈瑞生物医疗电子股份有限公司（以下简称"迈瑞医疗"） 发布2025年三季报。数据显示，第三季度，公司实现营收90.91亿元， ...

Group 1 - The 91st China International Medical Equipment Fair (CMEF) opened in Shanghai, showcasing nearly 5,000 brand enterprises with a theme of "Innovative Technology Leading the Future" [1] - Mindray Medical presented over 40 innovative products, including the world's first clinical application of a critical care large model, the Qiyuan model, which enhances clinical capabilities [1][3] - Mindray's AI solutions, "Digital Laboratory" and "Ruiying Ecosystem," focus on integrating "Equipment + IT + AI" to empower medical services across various clinical scenarios [5] Group 2 - The Qiyuan critical care large model has been implemented in several top medical institutions in China, marking a significant step in the application of general models in specialized medical fields [5] - Mindray's "Digital Laboratory" achieves breakthroughs in "Digital Testing," "Digital Operations," and "Digital Development" through deep integration of technology [5] - The "Ruiying Ecosystem" provides comprehensive AI solutions across obstetrics, radiology, cardiovascular, and point-of-care testing, enhancing the medical imaging digital ecosystem [5] Group 3 - Mindray has emphasized global expansion, adapting to challenges in international markets, particularly in response to recent U.S. tariff policies [7] - Despite tariffs since 2018, Mindray's U.S. business has seen a compound annual growth rate of 10% from 2018 to 2023, with U.S. sales accounting for a significant portion of total revenue [8] - The company plans to strengthen its position in the North American high-end market with products like the Resona A20, while also focusing on growth in developing countries, which account for two-thirds of overseas revenue [8]